Source: Business Wire

Press Release: Vivasure : Vivasure Medical Announces Enrollment of First Patients in Pivotal PATCH Study

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has enrolled the first patients in the company's PerQseal® PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal Closure Device System. The first patients were enrolled at Kaleida Health's Buffalo General Medical Center-Gates Vascular Institute in Buffalo, New York by

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Andrew Glass's photo - CEO of Vivasure

CEO

Andrew Glass

CEO Approval Rating

90/100

Read more